Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Breast Cancer · Multiple Sclerosis (MS)

HOFFMANN-LA ROCHE

Hoffmann-La Roche

HOFFMANN-LA ROCHE clinical programs — 286 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Mississauga, Ontario L5N 5M8, CA HQ
10 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Mississauga, Ontario L5N 5M8, CA
Employees
10
Programs
286
Drugs
212
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Programs

HOFFMANN-LA ROCHE projects

286 ClinicalTrials.gov programs sponsored by HOFFMANN-LA ROCHE.

HOFFMANN-LA ROCHE has 286 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

286 programs

Clinical programs

Page 3 of 6

  1. Taselisib

    Hoffmann-La Roche

    Breast Cancer

    phase 3 small molecule terminated

    1 trial

  2. Taxane

    Hoffmann-La Roche

    Gastric Cancer

    phase 3 small molecule terminated

    1 trial

  3. Tecentriq 1 200 mg concentrate for solution for infusion

    Hoffmann-La Roche

    Cancer (Future parent protocols may include other cancer that are not included in this section)

    phase 3 small molecule active

    1 trial

  4. Tiragolumab

    Hoffmann-La Roche

    Esophageal Squamous Cell Carcinoma

    phase 3 small molecule active

    1 trial

  5. Tocilizumab 162 mg

    Hoffmann-La Roche

    Rheumatoid Arthritis

    phase 3 small molecule completed

    1 trial

  6. Trastuzumab

    Hoffmann-La Roche

    Metastatic Breast Cancer

    phase 3 small molecule terminated

    1 trial

  7. Trastuzumab Emtansine

    Hoffmann-La Roche

    Metastatic Breast Cancer

    phase 3 small molecule terminated

    1 trial

  8. Trastuzumab emtansine

    Hoffmann-La Roche

    Breast Cancer

    phase 3 small molecule completed

    3 trials

  9. Vamikibart

    Hoffmann-La Roche

    Uveitic Macular Edema

    phase 3 small molecule completed

    1 trial

  10. Vemurafenib

    Hoffmann-La Roche

    Malignant Melanoma

    phase 3 small molecule completed

    2 trials

  11. WA40404

    Hoffmann-La Roche

    Primary progressive multiple sclerosis (PPMS)

    phase 3 small molecule active

    1 trial

  12. WA41937

    Hoffmann-La Roche

    Primary Membranous Nephropathy (pMN)

    phase 3 small molecule active

    1 trial

  13. WA43380

    Hoffmann-La Roche

    Childhood Idiopathic Nephrotic Syndrome

    phase 3 small molecule active

    1 trial

  14. WC45725

    Hoffmann-La Roche

    Obesity or Overweight Without Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  15. WC45726

    Hoffmann-La Roche

    Obesity or Overweight and Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  16. WN42086

    Hoffmann-La Roche

    Relapsing-Remitting Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  17. WN43174

    Hoffmann-La Roche

    NMDAR or LGI1 mediated autoimmune Encephalitis

    phase 3 other active

    1 trial

  18. WN43194

    Hoffmann-La Roche

    Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)

    phase 3 other active

    1 trial

  19. WN45443

    Hoffmann-La Roche

    Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia Due to AD)

    phase 3 small molecule active

    1 trial

  20. WN45447

    Hoffmann-La Roche

    Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia due to AD)

    phase 3 small molecule active

    1 trial

  21. WO29637

    Hoffmann-La Roche

    Renal Cell Carcinoma

    phase 3 small molecule completed

    1 trial

  22. WO41535

    Hoffmann-La Roche

    High-risk hepatocellular carcinoma (HCC)

    phase 3 small molecule active

    1 trial

  23. WO41554

    Hoffmann-La Roche

    HR+/HER2-Negative Locally Advanced or Metastatic Breast cancer with PIK3CA mutation

    phase 3 small molecule active

    1 trial

  24. WO41994

    Hoffmann-La Roche

    Renal cell carcinoma (RCC)

    phase 3 small molecule active

    1 trial

  25. WO42633

    Hoffmann-La Roche

    Early human epidermal growth factor receptor 2 (HER2) positive breast cancer

    phase 3 small molecule active

    1 trial

  26. WO45654

    Hoffmann-La Roche

    Endocrine-Sensitive phosphatidylinositol 3-kinase (PIK3CA)-Mutated, Hormone Receptor-Positive, human epidermal growth factor receptor 2- (HER2-) negative advanced breast cancer

    phase 3 small molecule active

    1 trial

  27. WO46069

    Hoffmann-La Roche

    Pretreated Unresectable Locally Advanced or Metastatic human epidermal growth factor receptor 2 (HER2)-Positive Breast Cancer, with or without Central Nervous System (CNS) Metastases

    phase 3 small molecule active

    1 trial

  28. WP45338

    Hoffmann-La Roche

    Type 3 Von Willebrand Disease

    phase 3 small molecule active

    1 trial

  29. WR42221

    Hoffmann-La Roche

    Neovascular age-related macular degeneration (nAMD)

    phase 3 small molecule active

    1 trial

  30. YO29232

    Hoffmann-La Roche

    Carcinoma, Non-Small-Cell Lung

    phase 3 small molecule completed

    1 trial

  31. YO42137

    Hoffmann-La Roche

    Unresectable Esophageal Squamous Cell Carcinoma

    phase 3 small molecule active

    1 trial

  32. erlotinib

    Hoffmann-La Roche

    Non-Squamous Non-Small Cell Lung Cancer

    phase 3 small molecule completed

    1 trial

  33. lebrikizumab

    Hoffmann-La Roche

    Asthma

    phase 3 small molecule completed

    2 trials

  34. mycophenolate mofetil (CellCept)

    Hoffmann-La Roche

    Myasthenia Gravis, Generalized

    phase 3 small molecule completed

    1 trial

  35. obinutuzumab

    Hoffmann-La Roche

    Lymphocytic Leukemia, Chronic

    phase 3 small molecule completed

    1 trial

  36. peginterferon alfa-2a

    Hoffmann-La Roche

    Hepatitis C, Chronic

    phase 3 small molecule completed

    2 trials

  37. pioglitazone

    Hoffmann-La Roche

    Diabetes Mellitus Type 2

    phase 3 small molecule completed

    1 trial

  38. tocilizumab [RoActemra/Actemra]

    Hoffmann-La Roche

    Rheumatoid Arthritis

    phase 3 small molecule completed

    3 trials

  39. ALECTINIB

    Hoffmann-La Roche

    ALK fusion-positive extracranial solid or primary CNS tumors who have progressed following prior treatment or who have no satisfactory treatment available

    phase 2 small molecule active

    1 trial

  40. Alogabat

    Hoffmann-La Roche

    Angelman Syndrome

    phase 2 small molecule completed

    1 trial

  41. Atezolizumab

    Hoffmann-La Roche

    Advanced Liver Cancers

    phase 2 small molecule active

    1 trial

  42. BC45538

    Hoffmann-La Roche

    Obesity

    phase 2 small molecule active

    1 trial

  43. BN44619

    Hoffmann-La Roche

    Spinal Muscular Atrophy (SMA)

    phase 2 small molecule active

    1 trial

  44. BN45398

    Hoffmann-La Roche

    Duchenne Muscular Dystrophy (DMD)

    phase 2 other active

    1 trial

  45. BO25430

    Hoffmann-La Roche

    Metastatic Cancer

    phase 2 small molecule active

    1 trial

  46. BO39610

    Hoffmann-La Roche

    Metastatic non-small cell lung cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  47. BO41932

    Hoffmann-La Roche

    Solid tumors

    phase 2 small molecule active

    1 trial

  48. BO42533

    Hoffmann-La Roche

    Squamous cell carcinoma of the head and neck (SCCHN)

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does HOFFMANN-LA ROCHE have?

286 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.